- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.04. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | Longeveron Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 08.04. | Longeveron receives China patent for stem cell potency assay | 5 | Investing.com | ||
| 08.04. | Longeveron erhält chinesisches Patent für Testverfahren von Stammzellen | 1 | Investing.com Deutsch | ||
| 08.04. | Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) | 1 | GlobeNewswire (USA) | ||
| 24.03. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | Longeveron Announces 2025 Full Year Financial Results and Provides Business Update | 1.004 | GlobeNewswire (Europe) | On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric... ► Artikel lesen | |
| 17.03. | Longeveron Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 12.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | Longeveron Announces Closing of Private Placement of up to $30 Million | 6 | GlobeNewswire (USA) | ||
| 11.03. | A $30 Million Reason to Buy Penny Stock Longeveron Today | 6 | Barchart.com | ||
| 10.03. | Longeveron secures $15M financing, eyes $15M more on trial results | 5 | Investing.com | ||
| 25.02. | Longeveron publishes phase 2b stem cell trial results in journal | 3 | Investing.com | ||
| 25.02. | Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell | 541 | GlobeNewswire (Europe) | MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic... ► Artikel lesen | |
| 13.02. | Longeveron ernennt Stephen Willard vor entscheidenden Studienergebnissen zum neuen CEO | 2 | Investing.com Deutsch | ||
| 13.02. | Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results | 2 | Investing.com | ||
| 13.02. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.02. | Longeveron Appoints Stephen H. Willard as Chief Executive Officer | 264 | GlobeNewswire (Europe) | Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant... ► Artikel lesen | |
| 13.02. | Longeveron appoints new CEO | 1 | Seeking Alpha | ||
| 05.02. | Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 44,635 | +0,08 % | What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. | ||
| OCUGEN | 1,468 | -0,68 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| EDITAS MEDICINE | 2,510 | -1,95 % | Editas Medicine stellt präklinische Daten zur LDL-senkenden Therapie EDIT-401 vor | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,300 | -3,74 % | Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know | ||
| DENALI THERAPEUTICS | 16,035 | +0,60 % | What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | CSE Bulletin: Suspension - SOL Global Investments Corp. (SOL) | Le 7 avril/April 2026
Effective immediately, SOL Global Investments Corp. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,080 | +1,79 % | Fate Therapeutics, Inc.: Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR - East 2026 Meeting | ||
| TRINITY BIOTECH | 0,613 | +1,24 % | TRINITY BIOTECH PLC - 20-F, Annual and transition report of foreign private issuers | ||
| ARCTURUS THERAPEUTICS | 8,715 | +0,98 % | Cathie Wood's ARK sells Nvidia stock, buys Arcturus Therapeutics | ||
| VOYAGER THERAPEUTICS | 3,200 | +0,82 % | Voyager Therapeutics, Inc.: Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease | ||
| ANAVEX LIFE SCIENCES | 2,849 | +3,94 % | ANAVEX LIFE SCIENCES CORP in ruhiger Aufbauphase | ||
| BIOAGE LABS | 14,500 | +0,97 % | BioAge Labs, Inc.: BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP | 120 mg and newly announced 60 mg once-daily doses each achieved =85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose... ► Artikel lesen | |
| CERUS | 1,710 | -1,16 % | Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System | Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood... ► Artikel lesen | |
| LINEAGE CELL THERAPEUTICS | 1,438 | +11,30 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien | ||
| OVID THERAPEUTICS | 2,360 | 0,00 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen |
LONGEVERON INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,022 (+2,51 %) liegt der Kurs bei 0,879 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.